{"schema_version":"secwatch.filing_event.v1","accession":"0000939767-24-000149","form_type":"8-K","ticker":"EXEL","cik":"0000939767","company_name":"EXELIXIS, INC.","filed_at":"2024-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.443565+00:00","generated_at":"2026-05-30T09:33:32.964439+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Exelixis Q3 revenue $539.5M, EPS $0.40; raises FY 2024 guidance","bullets":["Q3 net product revenue $478.1M (cabozantinib franchise) vs $426.5M YoY, +12%.","GAAP diluted EPS $0.40, non-GAAP diluted EPS $0.47; prior year $0.00 and $0.10.","Raises 2024 total revenue and net product revenue guidance on strong commercial performance.","Favorable U.S. District Court ruling on cabozantinib patent litigation received.","New collaboration with Merck adds two phase 3 trials for zanzalintinib in renal cell carcinoma."],"urls":{"canonical":"https://secwatch.observer/filing/0000939767-24-000149","json":"https://secwatch.observer/filing/0000939767-24-000149.json","markdown":"https://secwatch.observer/filing/0000939767-24-000149.md","text":"https://secwatch.observer/filing/0000939767-24-000149.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/939767/000093976724000149/0000939767-24-000149-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/939767/000093976724000149/exel-20241029.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T09:33:32.964439+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}